1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6211)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13088)
  2. Department of Medicine (13004)
  3. Center for Hematologic Malignancies (10395)
  4. GSK Faculty (4422)
  5. Adult Leukemia (3583)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (775)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (204)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (431)

More Publishers

Results (13088)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment-free remission (TFR) in patients with chronic-phase chronic myeloid leukemia (CML-CP) with stable deep molecular response (DMR) discontinuing dasatinib (DASFREE)
    Meeting Abstract

    Shah, N. P.; Garcia-Gutierrez, J. V.; Jimenez-Velasco, A.; Larson, S.; Saussele, S.; Rea, D.; Mahon, F. X.; Levy, M. Y.; Gomez-Casares, M. T.; Pane, F.; more...
    British Journal of Haematology (2018)

    Fulltext@MSK | Save
  • Efficacy and safety of first-line bosutinib versus imatinib in the BFORE trial: 18-month follow-up
    Meeting Abstract

    Clark, R. E.; Gambacorti-Passerini, C.; Deininger, M.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Dyagil, I.; Glushko, N.; Milojkovic, D.; Le Coutre, P.; more...
    British Journal of Haematology (2018)

    Fulltext@MSK | Save
  • A validated risk model for overall survival in relapsed/refractory chronic lymphocytic leukaemia applicable to patients treated with novel therapies and standard of care
    Meeting Abstract

    Hillmen, P.; Soumerai, J.; Zelenetz, A.; Darif, M.; Londhe, A.; Xing, G.; Huang, J.; Lin, M.; Byrd, J.; Chanan-Khan, A.; more...
    British Journal of Haematology (2018)

    Fulltext@MSK | Save
  • Venetoclax (VEN) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL)
    Meeting Abstract

    Davids, M.; Roberts, A.; Seymour, J.; Wierda, W.; Puvvada, S.; Gressick, L.; Alter, D.; Zhou, L.; Kim, S.; Verdugo, M.; more...
    British Journal of Haematology (2018)

    Fulltext@MSK | Save
  • Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukaemia treated with idelalisib
    Meeting Abstract

    Hillmen, P.; Brown, J.; Zelenetz, A.; Furman, R.; Lamanna, N.; Mato, A.; Montillo, M.; O'Brien, S.; Dreiling, L.; Dubowy, R.; more...
    British Journal of Haematology (2018)

    Fulltext@MSK | Save
  • Outcomes of patients with metastatic melanoma selected for surgery after immunotherapy
    Meeting Abstract

    Bello, D. M.; Panageas, K. S.; Hollmann, T. J.; Shoushtari, A. N.; Chapman, P.; Postow, M. A.; Callahan, M. K.; Wolchok, J. D.; Brady, M. S.; Coit, D.; more...
    Annals of Surgical Oncology (2018)

    Fulltext@MSK | Save
  • Seizure rates in enzalutamide-treated men with metastatic castration-resistant prostate cancer and risk of seizure: The UPWARD study
    Journal Article

    Slovin, S.; Clark, W.; Carles, J.; Krivoshik, A.; Park, J. W.; Wang, F.; George, D.
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: A CIBMTR analysis
    Journal Article

    Shah, N. N.; Ahn, K. W.; Litovich, C.; Fenske, T. S.; Ahmed, S.; Battiwalla, M.; Bejanyan, N.; Dahi, P. B.; Bolaños-Meade, J.; Chen, A. I.; more...
    Blood Advances (2018)

    Fulltext@MSK | Save
  • Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily
    Journal Article

    Moskowitz, C. H.
    Blood Advances (2018)

    Fulltext@MSK | Save
  • Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
    Journal Article

    Herrera, A. F.; Moskowitz, A. J.; Bartlett, N. L.; Vose, J. M.; Ramchandren, R.; Feldman, T. A.; LaCasce, A. S.; Ansell, S. M.; Moskowitz, C. H.; Fenton, K.; more...
    Blood (2018)

    Fulltext@MSK | Save